Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Free Webinar - Master Forex Trading Today! Don't Miss Out | Tuesday, June 6, 2023 | 01:00PM EDT Enroll Now
Close

Cardiff Oncology Inc (CRDF)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Cardiff Oncology's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1.630 0.000    0.00%
15:06:17 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 75,403
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.601 - 1.650
Cardiff Oncology 1.630 0.000 0.00%

Cardiff Oncology Inc Company Profile

 
Get an in-depth profile of Cardiff Oncology Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The Company has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The Company has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.

Contact Information

Address 11055 Flintkote Avenue
San Diego, 92121
United States
Phone 858 952 7570
Fax -
Web www.cardiffoncology.com

Top Executives

Name Age Since Title
Sandra L. Silberman 65 2017 Member of Clinical Advisory Board
Filip Janku 47 - Member of Clinical Advisory Board
Emmanuel Antonarakis - 2020 Member of Clinical Advisory Board
Mark Erlander 61 2013 CEO & Director
Rodney S. Markin 64 2014 Independent Chairman of the Board
Gary W. Pace 73 2020 Independent Director
Renee P. Tannenbaum 70 2021 Independent Director
Lale White 66 2020 Independent Director
Carlo Maria Croce - - Member of Scientific Advisory Board
Paul R. Billings 70 2012 Member of Scientific Advisory Board
Charles R. Cantor 79 - Member of Scientific Advisory Board
Michael B. Yaffe - 2018 Member of Clinical Advisory Board
Glenn J. Bubley - 2018 Member of Clinical Advisory Board
Heinz-Josef Lenz 62 2020 Member of Clinical Advisory Board
Alberto Bardelli - 2014 Member of Scientific Advisory Board
Brunangelo Falini - 2010 Member of Scientific Advisory Board
K. Peter Hirth 70 2014 Member of Scientific Advisory Board
James O. Armitage 75 2020 Independent Director
Mani Mohindru 50 2021 Independent Director
Amer Zeidan - 2020 Member of Clinical Advisory Board
Riccardo Dalla-Favera 70 2010 Member of Scientific Advisory Board
David Einstein - 2018 Member of Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CRDF Comments

Write your thoughts about Cardiff Oncology Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 30, 2022 7:09AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I really like this failure, I bought it for $ 3, I hope it will fly into the stratosphere soon!!!
Reply
0 0
Report
criptomonedas ripple cardano
criptomonedas ripple cardano Dec 03, 2021 1:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
cardiff 100$
Reply
2 0
Report
Joe Montana
Joe Montana Apr 26, 2021 10:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
about to pop
Reply
1 0
Report
Shahan Khan
Shahan Khan Mar 08, 2021 7:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
11.20 soon
Reply
3 0
Report
Dee Trinbagonian
Dee Trinbagonian Feb 27, 2021 3:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
To the moon 🚀
Reply
2 0
Report
Jobir Avezov
Jobir Avezov Feb 02, 2021 1:12PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Wow its going to gain sooner
Reply
1 0
Report
Aktieris Vanjaa
Aktieris Vanjaa Jan 24, 2021 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zman Any tips for bull?
Reply
1 0
Report
Zman Trading
ZmanTrading Jan 24, 2021 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Setting SL $10.18 and still my short term target is $14.
Reply
0 0
Report
Zman Trading
ZmanTrading Jan 24, 2021 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zman Trading Don’t look right. Sold with loss at $10,34. Good luck to those who still hang on!
Reply
0 0
Report
Jobir Avezov
Jobir Avezov Jan 24, 2021 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zman Trading No hopes mate
Reply
0 0
Report
Aaron Strong
Aaron Strong Jan 24, 2021 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zman Trading good call👎
Reply
0 0
Report
Ahmad AL-s
Ahmad AL-s Jan 24, 2021 12:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zman Trading  i think its a good buy now
Reply
0 0
Report
Zman Trading
ZmanTrading Jan 24, 2021 11:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://seekingalpha.com/article/4400581-first-look-cardiff-oncology
Reply
1 0
Report
Zman Trading
ZmanTrading Jan 21, 2021 4:17PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
In green! Very important step in the right direction. Price is at +11.45% from yesterdays low!
Reply
2 0
Report
Zman Trading
ZmanTrading Jan 21, 2021 4:17PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Higher high and higher low on the daily!
Reply
0 0
Report
Zman Trading
ZmanTrading Jan 20, 2021 4:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Strong finish! Almost 10% up from todays low at $10.21. Signals further upside $$$
Reply
2 0
Report
Jobir Avezov
Jobir Avezov Jan 20, 2021 4:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What is your price predictions about today
Reply
0 0
Report
Zman Trading
ZmanTrading Jan 20, 2021 4:03PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Jobir Avezov  Right now it's testing yesterdays closing price. Most important thing today imo is to close above this price - $11.14. If so, I expect further upside. Extremely volatile atm. Impossible to predict but a close above $12 would be super bullish imo.
Reply
3 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email